REAL-WORLD BIOLOGIC USE AND SWITCHING AMONG ADULTS WITH SEVERE ASTHMA TREATED BY US SUBSPECIALISTS IN THE CHRONICLE STUDY

SESSION TITLE: Asthma-Specific Biologics Abstract Posters TYPE: Original Investigation PRESENTED ON: 10/18/2022 01:30 pm - 02:30 PURPOSE: Multiple biologic therapies are now available for severe asthma (SA) treatment and can improve outcomes patients. However, few data describing the real-world use switching between multiple approved biologics by subspecialists (pulmonologists allergist/immunologists) in United States (US). We sought to examine a large cohort of subspecialist-treated US adults with SA. METHODS: CHRONICLE is an ongoing, noninterventional study SA receiving therapy, maintenance systemic corticosteroids (mSCS), or those persistently uncontrolled high-dose inhaled additional controllers. For enrolled patients, sites report exacerbations medication starting from 12 months before enrollment. patients February 2018 2021, were described. Biologic therapy switches defined as stopping 1 different within 6 months. RESULTS: Among 2793 2025 (73%) had any use. changed substantially more approved. From October through benralizumab (33%) dupilumab (34%) most frequently initiated. Overall, 324 (16%) 404 switches. Any switch was reported 1.6% November 2015 2017, 13.7% 2017 2018, 25.8% since 2018. During these time intervals, proportions (two more) 1.0%, 6.5%, 5.7%, simultaneous dual 1.2%, 2.4%, 2.7%, respectively. In two recent periods, common which switched dupilumab. Compared who ongoing use, likely be younger, have commercial insurance, employed full-time used mSCS prior CONCLUSIONS: Real-world occurred approximately becoming increasingly approval biologics. CLINICAL IMPLICATIONS: Switching allergists/immunologists pulmonologists. DISCLOSURES: Employee relationship AstraZeneca Please note: >$100000 Christopher Ambrose, value=Salary stockholder 2 years Added 03/31/2022 Donna Carstens, Speaker/Speaker's Bureau $5001 $20000 Bradley Chipps, value=Honoraria Boeringer Ingelheim Genentech Consultant GlaxoSmithKline value=Consulting fee Novartis Regeneron Sanofi Genzyme LP Since 2014 Eduardo Genofre, Shareholder value=LTIs Research support institution 2005-2022 03/30/2022 Dennis Ledford, value=Grant/Research Support Genentech/Roche 2000-2022 2019-2022 ALK $1001 $5000 Removed Ledford Boehringer $1-$1000 consultant GSK 2000-2001 Amgen 2021-2022 Scientific Medical Advisor 2017-2022 Advisory Committee Member BioCryst 2020-2022 AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, Teva >24 Njira Lugogo, Clinical trial funding TEVA, Gossamer Avillion TEVA Funds developing CME presentations AKH, Medscape NACE money received Janssen 08/2020 Present No relevant relationships Arjun Mohan 24 03/29/2022 Reynold Panettieri, Panettieri RIFM Equillium Genetech Sanofi/Regeneron Bayer Theravance Contracted Optikira Medimmune Maven Evelobio Johnson & AstraZeneca; RIFM; Equillium; Genentech; Thervance Sanofi/Regeneron; grant recipient Novartis; Optikira; Medimmune; Maven; Johnson; Principal Investigator $20001 $100000 MedImmune Reseaerch Institute Fragrance Materials OncoArendi Metera Origo ACTIV-1 Vault Health Merck Co PackHealth Weily Soong, Grant: 8/2020 present 2020-present 2021-present 2022-present >5 Frank Trudo, value=Shares